EGFR and cancer: Univariable analysis (Table 3) showed shorter overall survival in association with socioeconomic deprivation, EGFR L858R mutations, distant disease at cancer diagnosis, initial choice of EGFR kinase inhibitor of gefitinib (vsversus erlotinib), age >65 years, non-Asian ethnicity, residence outside the Northern or Midlands regions, and adenocarcinoma morphology.